Mochida Pharmaceutical Co., Ltd.

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. Its portfolio includes treatments for cardiovascular, obstetric, gynecologic, dermatologic, psychiatric, and gastroenterologic conditions, such as Lialda, Omvoh, and Cortiment for ulcerative colitis; Goofice and Movicol for chronic constipation; Epadel for hyperlipidemia and arteriosclerosis obliterans; Urece for gout and hyperuricemia; Treprost for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; Atelec, a calcium channel blocker; Dinagest for endometriosis, adenomyosis, and dysmenorrhea; Lexapro, an antidepressant; Tamcet for chronic pain; Beselna for condyloma acuminatum and actinic keratosis; and Heparin Sodium MOCHIDA anticoagulants. The company also develops mesalazine for ulcerative colitis, tocilizumab for rheumatoid arthritis, dotinurad for gout and hyperuricemia, a dienogest formulation for dysmenorrhea, treprostinil for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, and icosapent for hypertriglyceridemia. It further develops medical devices, including dMD-001 for articular cartilage lesions, dMD-002 for cavernous nerve injury, and dMD-003 for post-operative adhesion, and is involved in the development, production, distribution, sale, and marketing of skincare products. Founded in 1913, the company is headquartered in Tokyo, Japan.